MINNEAPOLIS, March 10, 2011 /PRNewswire/ — American Medical
Systems® (AMS) (Nasdaq:
AMMD), a leading provider of world-class devices and therapies
for male and female pelvic health, today announced the results of a
six-month prospective multi-center study of the Elevate®
Anterior and Apical Prolapse Repair System. The pelvic organ
prolapse quantification exam (POP-Q), used to quantify, describe
and stage pelvic support, was implemented in the study and
concluded efficacy rates of Stage One or less to be 86.3% for
Anterior and 98.8% for Apical.
The study was conducted with 142 women who were enrolled at 16
centers located in the United States and Europe. When questioned
about quality of life benefits after receiving the procedure, 94.7
percent of patients reported feeling some or a lot of
improvement.
“The Elevate Anterior and Apical system, completed with a single
vaginal incision and no external needle passes, has shown at six
months to be effective at treating both anterior and apical
prolapse,” said Dr. Edward J. Stanford, principal investigator of
the study. “The results of this study were especially significant
given that many of the patients had severe Stage Three or Four
prolapse.”
Elevate is a minimally invasive, comprehensive solution to treat
anterior and apical defects. The total transvaginal approach is
designed to minimize tissue trauma. Elevate offers safe, simple and
precise apical mesh placement in the sacrospinous ligament through
a single vaginal incision.
“We are very pleased to see these positive efficacy rates
coupled with significant patient satisfaction,” stated John Nealon,
senior vice president and general manager of Women’s Health at AMS.
“This data continues to validate our technology and helps confirm
why Elevate is the top-selling prolapse repair system in the market
place.”
The Elevate Anterior and
‘/>”/>
SOURCE